10,000 heart patients enrolled in massive recovery study
NCT ID NCT07096973
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will follow 10,000 people who come to a clinic in Davos, Switzerland for cardiac rehabilitation after a heart attack, surgery, or other heart problem. Researchers will collect health data, blood samples, and genetic information to understand what helps people recover best. The goal is to find ways to personalize rehab for better long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could identify which factors (like genetics or lifestyle) most improve recovery after a heart event, leading to better, personalized rehab programs.
- What could go wrong
- This is an observational study, not a treatment trial. It will gather data but won't test a new drug or therapy, so it cannot directly cure or treat any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Aug 2040
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients referred to HGK for inpatient CR will be screened for eligibility according to inclusion and exclusion criteria. Study inclusion requires written informed consent, and the study and all -related procedures will be performed according to the Declaration of Helsinki. The study plans to enroll approximately 1'000 patients per year.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients undergoing CR at the HGK * Written informed consent * Age ≥ 18 years Exclusion Criteria: * Insufficient knowledge of the German language to understand study documents, the interview, or questionnaires interview without translation * Physical or psychological incapability to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acs (acute coronary syndrome) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hochgebirgsklinik Davos
RECRUITINGDavos, Kanton Graubünden, 7265, Switzerland
Contact Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Thymus cells may teach a new heart to be left alone
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a new care pathway speed up advanced heart failure decisions?
- Can daily mindful breathing ease heart failure symptoms?
- The heart rhythm threat hiding in heart attack wards
- Can a smartphone app keep heart failure patients out of the hospital?